PGEN Earnings — Precigen, Inc. Common Stock Post-ER Performance | BigEarnings
PGEN — Precigen, Inc. Common Stock
XNAS · Healthcare · Biotechnology
Price$6.95
Market Cap$2.5B
P/E—
52W Range$2.99 – $7.71
Next Earnings2026-11-12
About Precigen, Inc. Common Stock
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
